3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Sarcoma
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Fulvestrant
81
Letrozole
74
Paclitaxel
71
pembrolizumab
67
Specimen Handling
63
Trastuzumab
60
Carboplatin
55
Magnetic Resonance Spectroscopy
50
ribociclib
47
Capecitabine
47
Anastrozole
45
palbociclib
44
pertuzumab
43
Tamoxifen
38
Cyclophosphamide
38
exemestane
37
abemaciclib
37
Biopsy
35
trastuzumab deruxtecan
30
Docetaxel
28
Taxes
27
Gemcitabine
25
Radiotherapy
24
Surveys and Questionnaires
23
130-nm albumin-bound paclitaxel
23
Standard of Care
21
Blood Specimen Collection
21
sacituzumab govitecan
20
olaparib
20
eribulin
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
MK 2206
×
Breast
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled